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ABSTRACT
Background: Intra-articular injection of hyaluronan (HA)
has been suggested to have a disease-modifying effect in
osteoarthritis, but little is known about the possible
mechanisms.
Objective: To investigate the effects of HA species of
different molecular mass, including 800 kDa (HA800) and
2700 kDa (HA2700), on the expression of aggrecanases
(ie, ADAMTS species), which play a key role in aggrecan
degradation.
Methods: The effects of HA species on the expression of
ADAMTS1, 4, 5, 8, 9 and 15 in interleukin 1a (IL1a)-
stimulated osteoarthritic chondrocytes were studied by
reverse transcription PCR and real-time PCR. Expression of
ADAMTS4 protein and aggrecanase activity and signal
transduction pathways of IL1, CD44 and intracellular
adhesion molecule 1 (ICAM1) were examined by
immunoblotting.
Results: IL1a treatment of chondrocytes induced
ADAMTS4, and HA800 and HA2700 significantly
decreased IL1a-induced expression of ADAMTS4 mRNA
and protein. IL1a-stimulated aggrecanase activity in
osteoarthritic chondrocytes was reduced by treatment
with HA2700 or transfection of small interfering RNA for
ADAMTS4. A similar result was obtained when HA2700
was added to explant cultures of osteoarthritic cartilage.
HA2700 neither directly inhibited nor bound to ADAMTS4.
Downregulation of ADAMTS4 expression by HA2700 was
attenuated by treatment of IL1a-treated chondrocytes
with antibodies to CD44 and/or ICAM1. The increased
phosphorylation of IL1 receptor-associated kinase-1 and
extracellular signal-regulated protein kinase1/2 induced by
the IL1a treatment was downregulated by enhanced
IRAK-M expression after HA2700 treatment.
Conclusion: These data suggest that HA2700 sup-
presses aggrecan degradation by downregulating IL1a-
induced ADAMTS4 expression through the CD44 and
ICAM1 signalling pathways in osteoarthritic chondrocytes.
Aggrecan degradation and subsequent digestion of
collagen fibrils make up the central pathway for
the destruction of cartilage in osteoarthritis (OA).
Collagen degradation is carried out principally by
collagen-degrading matrix metalloproteinases
(MMPs) such as MMP1, MMP8 and MMP13.
1–3
On the other hand, aggrecan-degrading metallo-
proteinases, called aggrecanases, are considered to
play a key role in aggrecan degradation.
45
Aggrecanases belong to the ADAMTS (a disinte-
grin and metalloproteinase with thrombospondin
motifs) gene family, and ADAMTS1, 4, 5, 8, 9 and
15 are known to have aggrecanase activity.
46
Studies using ADAMTS4 and ADAMTS5 knockout
mice have indicated that ADAMTS5, but not
ADAMTS4, has an essential role in aggrecan
degradation in mice.
78 However, because there is
little information about the biochemical character,
expression patterns or gene promoter structures of
mouse ADAMTS4 and ADAMTS5, the data from
knockout mice must be interpreted with care and
should not be extrapolated to the human disease.
91 0
In human chondrocytes, ADAMTS4 is inducible by
treatment with cytokines such as interleukin 1 (IL1),
but the expression of ADAMTS5 is constitutive.
91 1 – 1 3
Our recent study also showed that, of the aggreca-
nase-type ADAMTS species, ADAMTS4 is selec-
tively overexpressed in human osteoarthritic
cartilage, with a direct correlation with the degree
of cartilage destruction, whereas ADAMTS5 is
constitutively expressed in both normal and osteoar-
thritic cartilage.
10 These results suggest that
ADAMTS4 is a major aggrecanase in human
osteoarthritic cartilage.
Hyaluronan (HA) is widely used to treat OA of
the knee by intra-articular injection. The effects are
reported to depend on the molecular mass of the
HA species,
14 15 which can be classified as very low
(50 kDa), low (300 kDa), medium (800 kDa) or
high (2000–3000 kDa) according to a consensus
reached at the 7th International Conference on
Hyaluronan (South Carolina, 2007). Symptom-
modifying effects of medium and high molecular
mass HA, including relief of joint pain, have been
demonstrated,
14 15 but some experimental and
clinical studies have provided evidence that these
HA species also have potentially disease-modifying
effects.
14 16–18 HA of 2700 kDa (HA2700) has been
shown to be a potent inhibitor of proteoglycan
release from the cell matrix of rabbit chondrocyte
cultures.
19 Previous studies
20 21 have also shown that
HA of 800 kDa (HA800) inhibits IL1-stimulated
production of MMP1, MMP3 and MMP13 through
interaction with CD44, a major receptor for HA on
chondrocytes and synoviocytes, although the
authors did not search for effects on the signalling
pathwayofCD44.Ontheotherhand,intra-articular
injection of HA800 in a rabbit OA model has been
reported to suppress osteoarthritic changes without
inhibiting expression of MMP3.
22 These data suggest
that the chondroprotective effect of medium and
high molecular mass HA may be due to inhibition of
aggrecanases as well as MMPs. At this juncture,
however, little or no information is available on the
effects of HA on aggrecanases in human osteoar-
thritic chondrocytes or cartilage.
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Ann Rheum Dis 2009;68:1051–1058. doi:10.1136/ard.2007.086884 1051In this study, we examined the effects of HA species on the
expression of ADAMTS1, 4, 5, 8, 9 and 15 in osteoarthritic
chondrocytes stimulated with IL1, one of the most powerful
stimulators of proteinase production.
23 As HA2700 inhibited IL1-
induced expression of ADAMTS4, we also studied the signalling
pathwaysthroughinteractionbetweenHA2700andHAreceptors.
METHODS
Chondrocyte cultures
Non-osteophytic articular cartilage was obtained at arthro-
plasty from knee or hip joints of patients with OA diagnosed
according to the criteria of the American College of
Rheumatology.
24 Chondrocytes were isolated from the carti-
lage,
25 and the cultured cells were confirmed to be of
chondrocyte phenotype by the positive immunostaining of
aggrecan and type II collagen.
26 Chondrocytes were starved of
serum in Dulbecco’s modified Eagle’s medium/Ham’s F-12
(DMEM/F-12) containing 0.2% lactalbumin hydrolysate, and
then treated with IL1a in the presence or absence of HA species
of different molecular mass, including 1.2 kDa (HAoligo),
300 kDa (HA300), 800 kDa (HA800) and 2700 kDa (HA2700),
all of which were gifts from Chugai Pharmaceutical Co (Tokyo,
Japan). The molecular mass of HA2700, which is known as
Suvenyl (Chugai Pharmaceutical Co) and used to treat knee OA,
was determined by the multi-angle laser light scattering
method.
27 We used 1 ng/ml IL1a and 2.5 mg/ml HA species
(except for HAoligo), as these concentrations of IL1a and HA
showed a definite stimulatory effect on ADAMTS4 expression
and a maximal inhibitory effect on IL1a-induced ADAMTS4
expression, respectively (data not shown). HAoligo was used at
a concentration of 250 mg/ml according to data from a previous
study.
28 The non-cytotoxic effect of these HA species on
cultured chondrocytes was confirmed using an MTT assay kit
(Nacalai Tesque Corp, Kyoto, Japan).
29 Informed consent was
obtained from patients according to the hospital ethics guide-
lines for the experimental use of the samples.
Reverse transcription (RT)-PCR
Total RNA extracted from cultured chondrocytes was reverse-
transcribed to cDNA, and PCR amplification by Ex Taq DNA
polymerase (Takara Bio, Otsu, Japan) was performed using
primers specific for ADAMTS1, ADAMTS4, ADAMTS5,
ADAMTS8, ADAMTS9, ADAMTS15, MMP1, MMP2, MMP3,
MMP13, membrane type (MT)1-MMP, MT4-MMP, tissue
inhibitor of metalloproteinases 3 (TIMP3) and the housekeeping
gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as
described previously.
10 30 31 Positive control experiments were
carried out as described elsewhere.
10
Real-time quantitative PCR
The relative mRNA expression ratios of ADAMTS1,
ADAMTS4, ADAMTS5, ADAMTS8, ADAMTS9 and
ADAMTS15 to GAPDH were measured in a TaqMan real-time
PCR assay as described previously.
32 Sequences of the primers
and TaqMan probe are provided as supplementary material 1.
Immunoblotting of ADAMTS4
Chondrocytes were cultured in serum-free DMEM/F-12 in the
presence or absence of IL1a. Cell lysates and conditioned
medium were subjected to sodium dodecyl sulphate/polyacry-
lamide gel electrophoresis (SDS/PAGE) under reduction,
33 and
immunoblotted with antibodies to ADAMTS4 (247-3F6 and
250-4F7) or GAPDH (Abcam, Cambridge, UK) as described
previously.
10 The specificity of monoclonal antibodies to the
spacer domain (247-3F6) or a portion of the disintegrin and
thrombospondin domains (250-4F7) of human ADAMTS4 has
been demonstrated.
10 Both antibodies were able to immunopre-
cipitate ADAMTS4 (supplementary material 2).
Figure 1 Effects of hyaluron (HA) species on mRNA expression of
ADAMTS species in interleukin (IL)1a-stimulated osteoarthritic
chondrocytes. (A) Reverse transcription-PCR analysis of the expression
of ADAMTS species and tissue inhibitor metalloproteinase 3 (TIMP3).
Total RNA was isolated from the chondrocytes which were treated for
24 h without (Cont) or with IL1a (1 ng/ml) and HA (250 mg/ml for
HAoligo and 2.5 mg/ml for other HA species), and reverse-transcribed
into cDNA followed by PCR. The experiments were carried out in
triplicate, and representative data are shown. Positive controls (PC) are
rheumatoid synovial fibroblasts for ADAMTS1, ADAMTS5 and TIMP3,
U-251 human glioblastoma cells for ADAMTS4, ADAMTS9 and
ADAMTS15, and CaR-1 rectal carcinoma cells for ADAMTS8.
10 (B) Real-
time PCR analysis of the mRNA expression of ADAMTS4. Relative
expression levels of ADAMTS4 in osteoarthritic chondrocytes treated
without (Cont) or with IL1a and HA species were normalised to an
endogenous control, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). Bars are mean (SD) (n=5). *p,0.05; **p,0.01;
***p,0.001.
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and articular cartilage
Chondrocytes were cultured for 5 days in serum-free DMEM/F-12
containing 100 mg/ml aggrecan isolated from porcine nasal
cartilage
34 in the presence or absence of IL1a. Aggrecanase
activity was detected by immunoblotting aggrecan fragments in
the medium using anti-aggrecan neoepitope (NITEGE
373)-
specific antibody (2 mg/ml).
35 The effects of HA2700, KB-
R7785 (a synthetic ADAM inhibitor)
32 36 and TIMP3 (a natural
inhibitor of aggrecanases)
37 38 on the aggrecanase activity of the
IL1a-stimulated chondrocytes were evaluated by immunoblot-
ting. Similarly, the effects of HA2700 and KB-R7785 on the
activity in osteoarthritic cartilage were examined by immuno-
blotting after culture of cartilage tissue slices (56561m m )i n
serum-free DMEM/F-12 containing 0.2% lactalbumin hydro-
lysate and IL1a. After the reactions, the samples were freeze-
milled under liquid nitrogen and pulverised.
25 The concentration
of glycosaminoglycan in proteoglycans extracted from the
cartilage powder was determined by colorimetric assay.
39 The
inhibitory activity of KB-R7785
32 36 on ADAMTS4 was con-
firmed in an assay of aggrecan digestion using recombinant
ADAMTS4
35 (data not shown).
Transfection of small interfering RNA (siRNA) for ADAMTS4
The siRNA for ADAMTS4 (CCATCAATGGAGATCCGGAGT)
(Ambion Inc, Austin, Texas, USA) and non-silencing oligonu-
cleotide (AATTCTCGGAACGTGTCACGT) (Qiagen Inc,
Valencia, California, USA) were custom synthesised and
transfected to IL1a-stimulated osteoarthritic chondrocytes and
cartilage (see supplementary material 3 for detailed conditions).
Expression of ADAMTS4 after siRNA transfection was mon-
itored by RT-PCR and immunoblotting, and aggrecanase
activity was detected by immunoblotting as describe above.
Blocking of HA2700 binding to chondrocytes with antibodies to
HA receptor, and analysis of cell signalling
Chondrocytes were incubated with neutralising CD44 antibody
(BD Biosciences, San Diego, California, USA), ICAM1 antibody
(Santa Cruz Biotechnology, Inc, Santa Cruz, California, USA) or
non-immune IgG (BD Biosciences), and then cultured in serum-
free DMEM/F-12 with or without HA2700 in the presence or
absence of IL1a. ADAMTS4 expression was monitored by RT-
PCR, real-time PCR and immunoblotting. For the study of cell
signalling, chondrocytes were cultured under similar conditions,
and the cell lysates were subjected to SDS/PAGE for immuno-
blotting analyses using rabbit polyclonal antibodies to IL1-
associated kinase 1 (IRAK1), phospho-IRAK1, IRAK-M, extra-
cellular signal-regulated protein kinase1/2 (ERK1/2) or phospho-
ERK1/2 (Cell Signalling Technology Co, Beverly, Massachusetts,
USA).
32 The effect of mitogen-activated protein kinase kinase
(MEK) inhibitor on ERK1/2 phosphorylation and expression of
ADAMTS4 was also examined by treating chondrocytes with
PD98059 (Calbiochem, San Diego, California, USA).
32 Detailed
conditions are described in supplementary material 4.
Figure 2 Effects of hyaluron (HA)
species on ADAMTS4 protein expression
in osteoarthritic chondrocytes.
Chondrocytes were cultured in the
absence (Cont) or presence of interleukin
(IL)1a (1 ng/ml) and HA (250 mg/ml for
HAoligo and 2.5 mg/ml for other HA
species) for 72 h, and then ADAMTS4
protein expression in cell lysates (A) and
culture medium (B) was analysed by
immunoblotting with ADAMTS4 antibody
(0.5 mg/ml; 250-4F7). Arrows indicate
ADAMTS4 of molecular mass 73 kDa and
58 kDa. The protein bands were
densitometrically analysed and
compared. Note that treatment with
HA800 and HA2700 significantly
decreased the level of expression of
ADAMTS4 protein in both cell lysates and
culture media. Bars are mean (SD)
(n=5). *p,0.05; **p,0.01;
***p,0.001. GAPDH, glyceraldehyde-3-
phosphate dehydrogenase.
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Comparisons between two groups were performed by the
Mann–Whitney U test. Comparisons among more than three
groups were made by the Kruskal–Wallis test. Statistical
analyses were carried out using Stat-View statistical software.
p,0.05 was considered significant.
RESULTS
Effects of HA on mRNA expression of ADAMTS species, MMPs
and TIMP3
RT-PCR analysis showed that IL1a treatment of osteoarthritic
chondrocytes induces expression of ADAMTS4 and stimulates
expression of TIMP3 (fig 1A). ADAMTS1, ADAMTS5 and
ADAMTS9 were constitutively expressed, and ADAMTS15
expression decreased under stimulation with IL1a. Negligible
expression of ADAMTS8 was observed even under IL1a
stimulation. When IL1a-stimulated chondrocytes were treated
with HA species, the expression of ADAMTS4, ADAMTS5 and
ADAMTS9 appeared to decrease in a manner directly related to
the molecular mass of the HA used (fig 1A). However, no
definite decrease in the expression of ADAMTS1, ADAMTS15
and TIMP3 was obtained by the treatment. Similar inhibitory
effects of the HA species on the IL1a-stimulated expression of
MMP3, MMP13, MT1-MMP and MT4-MMP were observed
(supplementary material 5).
Real-time PCR showed that the expression level of
ADAMTS4 was enhanced 17-fold by IL1a (p,0.001), and the
IL1a-induced expression was decreased to 70% and 50% by
treatment with HA800 (p,0.05) and HA2700 (p,0.01),
respectively, but not with HAoligo or HA300 (fig 1B). No
changes in ADAMTS1 expression level were observed in
chondrocytes treated or not with IL1a and/or HA species, and
negligible expression of ADAMTS8 was detected (supplemen-
tary material 6). Although the concentrations of ADAMTS5
and ADAMTS9 in the control and IL1a-treated samples did not
differ, they were significantly decreased by treatment with
HA2700 (p,0.05) (supplementary material 6). The level of
ADAMTS15 expression was significantly decreased after treat-
ment with IL1a (p,0.01), but no effects of HA species on the
expression were seen (supplementary material 6).
Effects of HA on protein expression of ADAMTS4
On immunoblotting, cell lysates from IL1a-stimulated chon-
drocytes but not control untreated chondrocytes showed a band
of 73 kDa, whereas a major band of 58 kDa was detected in
culture medium from IL1a-treated chondrocytes but not control
chondrocytes (fig 2A,B). These two ADAMTS4 species were
recognised by both antibodies (247-3F6 and 250-4F7). When the
IL1a-stimulated chondrocytes were treated with HA species, the
bands of ADAMTS4 appeared to decrease in an HA molecular
mass-dependent manner (fig 2A,B). Densitometric analysis
showed that the 73 kDa band was significantly decreased by
treatment with HA800 (p,0.05) and HA2700 (p,0.01), but not
with HAoligo or HA300 (fig 2A). The intensity of the 58 kDa
band was also significantly decreased with HA300 (p,0.01),
HA800 (p,0.01) and HA2700 (p,0.001), although it was
significantly increased with HAoligo (p,0.05) (fig 2B).
Inhibition of aggrecanase activity with HA2700
Aggrecanase activity was monitored by immunoblotting using
aggrecan neoepitope-specific antibody. As shown in fig 3A, non-
stimulated chondrocytes showed an immunoreactive band of
,70 kDa, and the intensity of the band increased after
Figure 3 Inhibition of aggrecanase activity by treatment of
osteoarthritic chondrocytes and cartilage tissue with hyaluron (HA)2700.
(A) Inhibition of interleukin (IL)1a-stimulated aggrecanase activity in
chondrocytes treated with HA2700. Osteoarthritic chondrocytes were
stimulated with IL1a (1 ng/ml) and treated with HA2700 (2.5 mg/ml),
KB-RR7785 (1 mM), tissue inhibitor of metalloproteinases 3 (TIMP3)
(100 nM), HAoligo (250 mg/ml) or buffer alone (None) in the presence of
porcine aggrecan (100 mg/ml). Culture media were subjected to
immunoblotting using aggrecan neoepitope-specific antibody (2 mg/ml).
(B) Inhibition of IL1a-stimulated expression of ADAMTS4 and
aggrecanase activity with small interfering RNA (siRNA) for ADAMTS4.
Chondrocytes were treated with siRNA for ADAMTS4 (TS4) or non-
silencing siRNA (NS), and expression of ADAMTS4 mRNA and protein
was determined by RT-PCR and immunoblotting (IB) with ADAMTS4
antibody (0.5 mg/ml; 250-4F7). Inhibition of aggrecanase activity was
evaluated by immunoblotting with aggrecan neoepitope antibody (2 mg/
ml). (C) Inhibition of IL1a-stimulated aggrecanase activity in
osteoarthritic cartilage tissue treated with HA2700. Cartilage tissue
slices were treated for 5 days with buffer alone (None), HA2700
(2.5 mg/ml), KB-R7785 (1 mM), non-silencing siRNA (NS) or siRNA for
ADAMTS4 (TS4) in the presence of IL1a (1 ng/ml), and then
aggrecanase activity was detected by immunoblotting with aggrecan
neoepitope antibody. Cont, cartilage tissue without IL1a treatment;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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IL1a-treated chondrocytes was reduced to basal level by
treatment with HA2700, and almost disappeared on treatment
with KB-R7785 or TIMP3, whereas no such inhibition was
observed with HAoligo (fig 3A). Transfection of IL1a-stimu-
lated chondrocytes with ADAMTS4 siRNA abrogated the
mRNA and protein expression of ADAMTS4, whereas no
changes in expression were obtained with non-silencing siRNA
(fig 3B). Accordingly, aggrecanase activity observed after IL1a
treatment decreased to basal level by transfection of ADAMTS4
siRNA but not non-silencing siRNA (fig 3B). Similar effects of
HA2700 and ADAMTS4 siRNA on aggrecanase activity were
obtained in osteoarthritic cartilage tissue slices: IL1a-induced
aggrecanase activity was reduced to basal level by treatment
with HA2700, KB-R7785 or siRNA (fig 3C).
When the direct action of HA2700 on ADAMTS4 was
examined, neither inhibition of ADAMTS4 activity nor binding
of ADAMTS4 species to HA2700 was observed (supplementary
material 7).
Involvement of CD44 and ICAM1 in inhibitory effect of HA2700
on ADAMTS4 expression
The inhibitory effect of HA2700 on ADAMTS4 expression was
partially attenuated by treatment with antibody to CD44
(p,0.05) or ICAM1, and almost completely with both
antibodies (p,0.01) (fig 4A), although the antibody showed
no effects on IL1a-induced ADAMTS4 expression (data not
shown). The effect of the antibody on HA2700-induced
inhibition of ADAMTS4 expression was confirmed by immuno-
blotting of cell lysates (fig 4B).
Figure 4 Analysis of the involvement of the CD44 and intracellular adhesion molecule 1 (ICAM1) signalling pathways in the HA2700 inhibitory effect
on ADAMTS4 expression. (A,B) Effect of CD44 antibody (aCD44) and ICAM1 antibody (aICAM1) on the inhibition of ADAMTS4 expression with
HA2700. Osteoarthritic chondrocytes were allowed to react for 1 h with buffer alone, non-immune IgG (20 mg/ml; data not shown), aCD44 (20 mg/ml),
aICAM1 (20 mg/ml) or aCD44 (20 mg/ml) + aICAM1 (20 mg/ml), treated with 2.5 mg/ml HA2700 for 24 h, and then cultured for 24 h for the real-time
PCR analysis of ADAMTS4 gene expression (A) and for 48 h for immunoblotting analysis of ADAMTS4 protein (B) after the addition of IL1a (1 ng/ml) to
the culture medium. Bars are mean (SD) (n=3). *p,0.05; **p,0.01. (C) Analysis of signalling pathways of IL1 and CD44 under treatment with
HA2700. Expression of IL1 receptor-associated kinase-1 (IRAK1), extracellular signal-regulated protein kinase1/2 (ERK1/2) and IRAK-M and
phosphorylation of IRAK1 and ERK1/2 were examined by immunoblotting of osteoarthritic chondrocytes. The cells were cultured for 24 h in the absence
(Cont and None) or presence (2.5 mg/ml) of HA2700, and then stimulated for 30 min without or with IL1a (1 ng/ml), followed by immunoblotting for p-
IRAK1, IRAK1, p-ERK1/2, ERK1/2 and IRAK-M. The effect of aCD44 on HA2700-induced signalling was examined as described above. (D) Involvement of
mitogen-activated protein kinase kinase (MEK) in ADAMTS4 expression and phosphorylation of ERK1/2. Chondrocytes were treated for 30 min without
or with PD98059 (50 mM). Then, the cells were cultured in the absence or presence of IL1a (1 ng/ml) for 48 h for immunoblotting of ADAMTS4 and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or for 30 min for immunoblotting of p-ERK1/2 and ERK1/2. All experiments were performed in
triplicate.
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ylation of IRAK1 and ERK1/2. The phosphorylation of both
molecules was enhanced by IL1a treatment, and the IL1a-
induced phosphorylation was downregulated by treatment
with HA2700 (fig 4C). HA2700 treatment of IL1a-treated or
untreated chondrocytes induced the expression of IRAK-M, a
negative regulator of IRAK1, via CD44.
40 Inhibition of IL1a-
induced phosphorylation of IRAK1 and ERK1/2 was attenuated
by treatment of the cells with CD44 antibody, and induction of
IRAK-M by HA2700 was abolished by incubation with the
antibody (fig 4C). In addition, phosphorylation of ERK1/2 and
expression of ADAMTS4 were abrogated by treatment with
PD98059, a MEK inhibitor (fig 4D). These results suggest that
IRAK-M induced by HA2700 binding to CD44 has a key role in
downregulation of the IL1a-stimulated signalling pathway, and
MEK is involved in the ERK1/2 phosphorylation.
DISCUSSION
Conflicting data have been reported on the expression of
aggrecan-degrading ADAMTS species: some studies have
reported that ADAMTS4 is upregulated by IL1, tumour necrosis
factor a, oncostatin M and transforming growth factor b,
21 21 3
but others have shown that IL1 treatment does not affect
ADAMTS4 expression.
41 42 Our systematic analyses of
ADAMTS4 expression in human osteoarthritic chondrocytes
under monolayer culture have provided the first evidence that
IL1a selectively induces ADAMTS4 expression, whereas
ADAMTS1, ADAMTS5 and ADAMTS9 are constitutively
expressed, and ADAMTS8 is negligibly expressed without being
affected by IL1a. Treatment of chondrocytes with tumour
necrosis factor a and oncostatin M has been reported to
downregulate ADAMTS15,
13 but our study showed that IL1a
also functions as a suppressor of ADAMTS15 expression.
Although previous studies have shown that HA800 sup-
presses the production of MMP1, MMP3 and MMP13 by
osteoarthritic and normal cartilage explants,
20 our study is the
first to show that 2.5 mg/ml of HA2700 and HA800, which is
within the physiological concentration range in synovial fluids
(2–4 mg/ml),
43 inhibits the mRNA and protein expression of
ADAMTS4 in osteoarthritic chondrocytes. The effect of HA is
known to depend on its molecular mass.
14 15 Indeed, our study
shows significant inhibition of ADAMTS4 expression with only
HA2700 and HA800, but not with HA300 or HAoligo. When
the effects were compared, HA2700 was considered to be the
more efficient suppressor of expression of aggrecan-degrading
ADAMTS species, as inhibition of ADAMTS4 expression
appeared to be greater with HA2700 than with HA800, and
HA2700, but not HA800, significantly inhibited the expression
of ADAMTS5 and ADAMTS9.
This study shows that IL1a-induced aggrecanase activity in
cultured chondrocytes and osteoarthritic cartilage explants is
suppressed by treatment with HA2700. Although TIMP3 is an
efficient inhibitor of ADAMTS4,
37 38 IL1a-stimulated TIMP3
expression appeared to be unchanged by HA2700 treatment.
HA2700 did not directly inhibit ADAMTS4 activity or bind to
ADAMTS4. siRNA for ADAMTS4 suppressed IL1a-induced
aggrecanase activity in cultured chondrocytes and cartilage
tissue. Therefore, these data suggest that HA2700 inhibition of
aggrecanase activity may be due principally to reduced
expression and production of ADAMTS4. On the other hand,
our finding that treatment with synthetic inhibitor and TIMP3
appeared to reduce aggrecanase activity to below that of
untreated osteoarthritic chondrocytes suggests that such strong
inhibition may be due to simultaneous suppression of aggreca-
nase(s) such as constitutively expressed ADAMTS5.
Previous studies have shown the involvement of CD44 in the
HA effects.
20 21 44 No previous studies have clarified the
intracellular signalling pathways. As binding of HA to CD44
on activated monocytes is known to modulate IL1-induced
signalling by inducing the expression of IRAK-M, which
suppresses IRAK1,
40 we examined the expression of these
signalling molecules. We found that HA2700 treatment reduces
IL1a-stimulated phosphorylation of IRAK1 and ERK1/2
through induction of IRAK-M. These data suggest that
Figure 5 Hypothesis of the signalling
pathways for HA2700 inhibition of
ADAMTS4 expression in IL1a-stimulated
osteoarthritic chondrocytes. The IL1a
signal via IL1 receptor is transduced by
IRAK1 and may enhance ADAMTS4
expression through the MAP kinase and
NF-kB pathways.
47 Binding of HA2700 to
CD44 induces IRAK-M, which inhibits
IRAK1 and subsequently suppresses
phosphorylation of ERK1/2 and finally
ADAMTS4 expression. HA2700 also
binds to ICAM1 and this binding may
inhibit NF-kB
48 and subsequently
suppress ADAMTS4 expression.
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pathway of IRAK1 and ERK1/2 by the action of IRAK-M (fig 5).
However, as the recovery with CD44 antibody was partial,
other pathways of HA receptors, including ICAM1
45 and Toll-
like receptor (TRL)2 and 4,
46 appear to be involved. In fact, the
finding that treatment with both CD44 antibody and ICAM1
antibody attenuated the inhibition suggests the involvement of
both CD44 and ICAM1 pathways (fig 5). It is, however,
unlikely that TRL2 and TRL4 act as receptors for HA in
osteoarthritic chondrocytes, as neither the expression of these
molecules nor any effect of their antibodies on the recovery was
observed in the chondrocytes (data not shown).
Intra-articular administration of HA2700 and HA800 is
widely used as a symptom-modifying treatment for knee
OA,
14 15 and growing experimental and clinical evidence suggests
that HA2700 and HA800 may also modify the structure of
diseased joints and slow the rate of OA disease progression. The
potential disease-modifying effect seems to be explained by
positive regulation of joint repair through stimulation of
chondrocyte growth metabolism and synthesis of cartilage
matrix and suppression of inflammatory processes.
14 However,
HA800 has been reported to inhibit the production of MMP1,
MMP3 and MMP13 in normal and osteoarthritic cartilage
treated with IL1b,
20 and the present study shows suppression of
ADAMTS4 expression by HA2700 and HA800. Thus, we
hypothesise that HA2700 and HA800 protect the cartilage from
damage in OA by inhibiting the expression of chondrodegrada-
tive metalloproteinases, ie, ADAMTS4 and MMPs. Clinical
trials of the disease-modifying effect of HA2700 on OA are
necessary.
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